InterAx Biotech SA

InterAx Biotech AG is a research-based Swiss company, spin-off from the ETH Zürich and the Paul Scherrer Institute (PSI). It has developed a unique drug discovery platform to reduce the time and costs for discovery and development of new drugs for a wide array of human diseases. InterAx technology combines in-vitro cell signaling experiments with mathematical modeling of signaling pathways and machine learning to discover new effective treatments and de-risk clinical trials.

Partnerships with leading pharmaceutical companies, Boehringer Ingelheim and Lundbeck, and South Korean biotech company, GPCR Therapeutics, allowed us to validate the technology platform. InterAx is currently applying its technology to an in-house drug discovery program in the field of oncology and has discovered a new molecular entity targeting solid tumours in several cancer subtypes with high unmet needs.